DAVID KULLING

Allopathic & Osteopathic Physicians|Family Medicine HEDGESVILLE, WV NPI 1528028800

General Payments — all program years on this page

$1,698.75

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 120
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $417.51 across 21 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $417.5121

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $377.2135
2019 $384.9734
2021 $143.908
2022 $336.6220
2023 $38.542
2024 $417.5121

Records — PY2024 (21)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1086122068 Bayer Healthcare Pharmaceuticals Inc. $30.01 08/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097409517 Novo Nordisk Inc $21.54 09/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104115368 ABBVIE INC. $18.75 04/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104115370 ABBVIE INC. $27.21 06/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104115372 ABBVIE INC. $28.71 07/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104386615 AstraZeneca Pharmaceuticals LP $21.03 06/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104398333 AstraZeneca Pharmaceuticals LP $20.08 04/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105402914 AstraZeneca Pharmaceuticals LP $18.63 03/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105488615 AstraZeneca Pharmaceuticals LP $16.72 03/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105742912 AstraZeneca Pharmaceuticals LP $18.92 05/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105865972 AstraZeneca Pharmaceuticals LP $21.90 03/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105878659 AstraZeneca Pharmaceuticals LP $16.45 12/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116242407 GlaxoSmithKline, LLC. $20.78 04/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116350170 GlaxoSmithKline, LLC. $20.73 04/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131237859 PFIZER INC. $13.63 03/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136125005 Lilly USA, LLC $13.64 10/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136130590 Lilly USA, LLC $14.21 11/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136133293 Lilly USA, LLC $18.08 08/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136141363 Lilly USA, LLC $14.72 07/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141874966 Merck Sharp & Dohme LLC $25.28 07/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141932069 Merck Sharp & Dohme LLC $16.49 11/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.